Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2 3Phase 1/2 1

Status

Recruiting 2Active not recruiting 1

Sponsor Class

INDUSTRY 2NETWORK 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Pancreatic Neoplasms 3

Interventions

pembrolizumab 60Carboplatin 60Paclitaxel 51Magnetic Resonance Spectroscopy 42Specimen Handling 41Cisplatin 41Gemcitabine 34Bevacizumab 31Docetaxel 30Leucovorin 27Doxorubicin 27Fluorouracil 26Dexamethasone 25Cyclophosphamide 25Pemetrexed 23Radiotherapy 22Radiation 22Oxaliplatin 22Etoposide 21durvalumab 20Nivolumab 20Vincristine 19Taxes 19Rituximab 19Irinotecan 19Prednisone 18Letrozole 18Capecitabine 17Lenalidomide 16Immunoglobulin G 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × irinotecan sucrosofate × 30 days × Clear all
NCT06625320 2026-06-02

RASolute 302

Revolution Medicines, Inc.

Phase 3 Active not recruiting
500 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT07409272 2026-06-02

A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer

Astellas Pharma Inc

Phase 3 Recruiting
614 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT06998940 2026-05-22

Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations

SWOG Cancer Research Network

Phase 3 Recruiting
94 enrolled
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡